Myriad Genetics Inc - Asset Resilience Ratio
Myriad Genetics Inc (MYGN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MYGN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Myriad Genetics Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Myriad Genetics Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Myriad Genetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Myriad Genetics Inc (MYGN) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Myriad Genetics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Myriad Genetics Inc Industry Peers by Asset Resilience Ratio
Compare Myriad Genetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Myriad Genetics Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Myriad Genetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $1.03 Billion | -- |
| 2023-12-31 | 0.77% | $8.80 Million | $1.15 Billion | -4.07pp |
| 2022-12-31 | 4.84% | $58.00 Million | $1.20 Billion | -1.32pp |
| 2021-12-31 | 6.16% | $81.40 Million | $1.32 Billion | +3.79pp |
| 2020-12-31 | 2.38% | $33.70 Million | $1.42 Billion | -0.42pp |
| 2019-12-31 | 2.80% | $43.70 Million | $1.56 Billion | -3.14pp |
| 2018-12-31 | 5.94% | $69.70 Million | $1.17 Billion | +1.99pp |
| 2017-12-31 | 3.94% | $48.30 Million | $1.22 Billion | -6.33pp |
| 2016-12-31 | 10.28% | $90.50 Million | $880.50 Million | -0.25pp |
| 2015-12-31 | 10.53% | $80.70 Million | $766.20 Million | -4.23pp |
| 2014-12-31 | 14.77% | $121.64 Million | $823.81 Million | -18.61pp |
| 2013-12-31 | 33.37% | $268.24 Million | $803.82 Million | -3.43pp |
| 2012-12-31 | 36.80% | $254.18 Million | $690.63 Million | -11.29pp |
| 2011-12-31 | 48.09% | $293.78 Million | $610.83 Million | -4.17pp |
| 2010-12-31 | 52.27% | $310.39 Million | $593.85 Million | -2.05pp |
| 2009-12-31 | 54.32% | $253.34 Million | $466.42 Million | +36.09pp |
| 2008-12-31 | 18.22% | $90.99 Million | $499.34 Million | -26.09pp |
| 2007-12-31 | 44.31% | $164.88 Million | $372.07 Million | -2.38pp |
| 2006-12-31 | 46.70% | $129.17 Million | $276.60 Million | +6.23pp |
| 2005-12-31 | 40.47% | $64.33 Million | $158.96 Million | +23.81pp |
| 2004-12-31 | 16.66% | $31.38 Million | $188.36 Million | +10.55pp |
| 2003-12-31 | 6.11% | $11.17 Million | $182.82 Million | -1.52pp |
| 2002-12-31 | 7.63% | $12.01 Million | $157.39 Million | -45.40pp |
| 2001-12-31 | 53.03% | $91.28 Million | $172.15 Million | +30.20pp |
| 2000-12-31 | 22.83% | $24.29 Million | $106.38 Million | +14.44pp |
| 1999-12-31 | 8.40% | $4.50 Million | $53.60 Million | -- |
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more